Hua Medicine of Shanghai has filed an Investigational New Drug (IND) application with the FDA to begin US clinical trials of its novel type 2 diabetes treatment, a 4th-generation glucokinase activator (GKA). In February, Hua filed to start a Phase II trial of sinogliatin in China, after reporting positive Phase Ib data. Hua in-licensed global rights to sinogliatin from Roche in 2011. In January, Hua completed a $25 million funding round to support the two trials.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
